- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00160069
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer
December 2, 2014 updated by: Bayer
Phase II Study to Investigate the Efficacy and Safety of ZK 219477 as Second Line Therapy in Patients With Stage IIIB or Stage IV Non Small Cell Lung Cancer (NSCLC)
Phase 2 study to investigate the efficacy and tolerability of epothilone ZK 219477 in patients with stage IIIb or stage IV non-small-cell lung cancer.
Study Overview
Status
Completed
Conditions
Detailed Description
The study has previously been posted by Schering AG, Germany.
Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Study Type
Interventional
Enrollment (Actual)
128
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany, 12200
-
Berlin, Germany, 14165
-
Bremen, Germany, 29325
-
Ebensfeld, Germany, 96250
-
Hamburg, Germany, 21075
-
-
Baden-Württemberg
-
Löwenstein, Baden-Württemberg, Germany, 74245
-
-
Bayern
-
Augsburg, Bayern, Germany, 86156
-
Gauting, Bayern, Germany, 82131
-
Nürnberg, Bayern, Germany, 90419
-
-
Hessen
-
Frankfurt, Hessen, Germany, 60590
-
Frankfurt, Hessen, Germany, 65929
-
-
Mecklenburg-Vorpommern
-
Greifswald, Mecklenburg-Vorpommern, Germany, 17475
-
Stralsund, Mecklenburg-Vorpommern, Germany, 17475
-
-
Sachsen
-
Leipzig, Sachsen, Germany, 04103
-
-
Sachsen-Anhalt
-
Halle, Sachsen-Anhalt, Germany, 06120
-
Magdeburg, Sachsen-Anhalt, Germany, 39130
-
-
Schleswig-Holstein
-
Großhansdorf, Schleswig-Holstein, Germany, 22927
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Non-small-cell lung cancer
- Only one previous chemotherapy with a platinum-containing drug
- Use of highly effective birth control methods in females of child-bearing potential
Exclusion Criteria:
- No more than 1 previous chemotherapy for advanced disease
- Previous participation in another trial within the last 4 weeks
- Breast feeding
- Active infections
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
|
16 mg/m2, 3-hour infusion, every 3 weeks
22 mg/m2, 30-min infusion, every 3 weeks
22 mg/m2, 3-hour infusion, every 3 weeks
|
Experimental: Arm 2
|
16 mg/m2, 3-hour infusion, every 3 weeks
22 mg/m2, 30-min infusion, every 3 weeks
22 mg/m2, 3-hour infusion, every 3 weeks
|
Experimental: Arm 3
|
16 mg/m2, 3-hour infusion, every 3 weeks
22 mg/m2, 30-min infusion, every 3 weeks
22 mg/m2, 3-hour infusion, every 3 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary efficacy variable is defined as Proportion of patients with either CR or PR as 'best overall response'. Tumor assessment is performed according to RECIST criteria.
Time Frame: Tumor evaluation (MRI or scan) every 2 cycles until disease progression.
|
Tumor evaluation (MRI or scan) every 2 cycles until disease progression.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary objectives : investigate the safety and tolerability of ZK 219477
Time Frame: Continuously
|
Continuously
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2005
Primary Completion (Actual)
April 1, 2008
Study Completion (Actual)
April 1, 2009
Study Registration Dates
First Submitted
September 8, 2005
First Submitted That Met QC Criteria
September 8, 2005
First Posted (Estimate)
September 12, 2005
Study Record Updates
Last Update Posted (Estimate)
December 4, 2014
Last Update Submitted That Met QC Criteria
December 2, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Epothilones
- Sagopilone
Other Study ID Numbers
- 91374
- 2005-000586-19 (EudraCT Number)
- 307971 (Other Identifier: Company Internal ID)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Non Small Cell Lung
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IA...United States
-
National Cancer Institute (NCI)Active, not recruitingLung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States, Puerto Rico
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Society of Thoracic RadiologyActive, not recruitingStage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
Clinical Trials on Sagopilone (BAY86-5302, ZK 219477)
-
BayerTerminatedSmall Cell Lung Carcinoma
-
BayerCompletedCarcinoma, Small CellGermany
-
BayerCompleted
-
BayerCompletedBreast NeoplasmUnited States, Canada
-
BayerCompletedBreast Neoplasms | Breast Cancer, MetastaticFrance, Germany, Spain, Austria, Belgium, Slovenia, Poland, Bulgaria, United Kingdom, Italy
-
BayerCompletedOvarian NeoplasmsUnited States, Canada
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Completed
-
BayerCompleted
-
H. Lee Moffitt Cancer Center and Research InstituteBayerCompleted
-
BayerCompletedProstate CancerUnited States, Argentina